STOCK TITAN
  1. Home
  2. Sec-filings
  3. VIR
  4. [8-K] Vir Biotechnology, Inc. Reports Material Event

Vir Biotechnology (NASDAQ: VIR) shares cash update, JPM talk details

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Vir Biotechnology, Inc. reported that it has issued a press release providing a preliminary estimate of its cash, cash equivalents and investments balance as of December 31, 2025. This figure is unaudited and may change, and the company plans to report its full fourth quarter and full-year 2025 financial results in late February 2026.

The company also plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:45 p.m. PT. The related slide deck is being made available as an exhibit and on the company’s investor website, which will also host a live webcast and a 30-day archive of the presentation.

Positive

  • None.

Negative

  • None.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What financial update did Vir Biotechnology (VIR) provide in this 8-K?

Vir Biotechnology provided a preliminary cash, cash equivalents and investments balance as of December 31, 2025. This information is contained in a press release attached as Exhibit 99.1 and is described as unaudited and subject to adjustment.

When will Vir Biotechnology (VIR) report its Q4 and full-year 2025 results?

The company stated that it expects to report its fourth quarter and full-year 2025 financial results in late February 2026.

What conference is Vir Biotechnology presenting at and when is the session?

Vir Biotechnology plans to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 3:45 p.m. PT in San Francisco, California.

Will Vir Biotechnology’s J.P. Morgan Healthcare Conference presentation be available online?

Yes. A live webcast of the presentation will be available on the company’s website at https://investors.vir.bio, and it will be archived there for 30 days.

How is the information in Items 2.02 and 7.01 treated under SEC rules?

The company states that the information in Item 2.02 and Item 7.01, including Exhibits 99.1 and 99.2, is being “furnished” and not “filed” for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless specifically referenced.

Where can investors access Vir Biotechnology’s investor presentation slides?

The presentation slides for the J.P. Morgan Healthcare Conference are attached as Exhibit 99.2 and will also be made available on the company’s investor website at https://investors.vir.bio.

FALSE000170643100017064312026-01-122026-01-120001706431exch:XNAS2026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
________________________________________
Vir Biotechnology, Inc.
(Exact name of Registrant as Specified in Its Charter)
________________________________________
Delaware001-3908381-2730369
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
1800 Owens Street, Suite 900
San Francisco, California 94158
(Address of Principal Executive Offices, including Zip Code)
Registrant’s Telephone Number, Including Area Code: (415) 906-4324
(Former Name or Former Address, if Changed Since Last Report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par valueVIRNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02 Results of Operations and Financial Condition.
On January 12, 2026, Vir Biotechnology, Inc. (the Company) issued a press release that, among other things, provided its preliminary cash, cash equivalents and investments balance as of December 31, 2025, and delivered an update on its business. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
These preliminary cash, cash equivalents and investments balance result is unaudited and subject to adjustment. The Company expects to report its fourth quarter and full-year 2025 financial results in late February 2026.
The information contained in this Item 2.02, including the attached Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure.
On January 14, 2026, the Company intends to present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will include the slides attached hereto as Exhibit 99.2 hereto and incorporated herein by reference. These slides will also be made available on the Company’s website at https://investors.vir.bio.
As previously announced, the presentation will take place at 3:45 p.m. PT on January 14, 2026 in San Francisco, California. A live webcast of the presentation will be made available on the Company’s website at https://investors.vir.bio and will be archived there for 30 days.
The information contained in this Item 7.01, including the attached Exhibit 99.2, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
Press Release of the Company, dated January 12, 2026
99.2
Investor Presentation of the Company, dated January 14, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VIR BIOTECHNOLOGY, INC.
Date:January 12, 2026By:/s/ Marianne De Backer
Marianne De Backer, M.Sc., Ph.D., MBA
Chief Executive Officer

Source: View Original Filing on SEC EDGAR